Posted On: 07/11/2016 3:47:37 PM
Post# of 72447
Tell me again how a company with the first entirely new class of antibiotic since 1987 is worth only 160.45 million market cap.
Not to mention Kevetrin, Prurisol, and Brilacidin-OM (and soon, Bril-UP) in clinical trials.
Absurd, isn't it?
Just talked myself into buying more.
Not to mention Kevetrin, Prurisol, and Brilacidin-OM (and soon, Bril-UP) in clinical trials.
Absurd, isn't it?
Just talked myself into buying more.
(0)
(0)
